First-line treatment of acute lymphoblastic leukemia with pegasparaginase

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 359-368

  Masetti, Riccardo ^a   Pession, Andrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute; Lymphoblastic leukemia; Pegasparaginase; Pegylation

Indexed keywords

EID: 77949927569     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S3295     Document Type: Review

References (101)

1. Apostolidou E, Swords R, Alvarado Y, et al. Treatment of acute lymphoblastic leukaemia: a new era. Drugs. 2007;67(15):2153-2171.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
3. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):64-75.
4. Ortega JA, Nesbit Jr ME, Donaldson MH, et al. l-Asparaginase, vincristine and prednisone for induction of first remission in acute lymphoblastic leukemia. Cancer Res. 1977;37(2):535-540.
5. Jones B, Holland JF, Glidewell O, et al. Optimal use of l-asparaginase (NSC-109229) in acute lymphoblastic leukemia. Med Pediatr Oncol. 1977;3(4):387-400.
6. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive l-asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315(11):657-663.
7. Schrappe M, Reiter A, Ludwig W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95(11):3310-3322.
8. Hann I, Vora A, Richards S, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukemia: results from MRC UKALL XI and MRC ALL97 randomized trials. Leukemia. 2000;14(3):356-363.
9. Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med. 1953;98(6):565-582.
10. Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: discussion. J Exp Med. 1953;98(6):583-606.
11. Mashburn LT, Wriston JC Jr. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys. 1964;105:450-452.
12. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161-7167.
13. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61(3):208-221.
14. Ertel IJ, Nesbit ME, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res. 1979;39(10):3893-3896.
15. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1(1):9-13.
16. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91(1):24-31.
17. Abuchowski A, Van Es T, Palczuk NC, et al. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-Lasparaginase. Cancer Treat Rep. 1979;63(6):1127-1132.
18. Yoshimoto T, Nishimura H, Saito Y, et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res. 1986;77(12):1264-1270.
19. Veronese FM, Mero A. The impact of PEGylation on biological therapies. Bio Drugs. 2008;22(5):315-329.
20. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-2739.
21. Campbell HA, Mashburn LT, Boyse EA, et al. Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity. Biochemistry. 1967;6(3):721-730.
22. Jackson RC, Handschumacher RE. Escherichia coli L-asparaginase. Catalytic activity and subunit nature. Biochemistry. 1970;9(18):3585-3590.
23. Maita T, Matsuda G. The primary structure of L-asparaginase from Escherichia coli. Hoppe Seylers Z Physiol Chem. 1980;361(2):105-117.
24. Whelan HA, Wriston JC Jr. Purification and properties of asparaginase from escherichia coli B. Biochemistry. 1969;8(6):2386-2393.
25. Chabner BA, Loo TL. Enzyme therapy: L-asparaginase. In: Cancer Chemotherapy and Biotherapy Principles. Chabner BA, Longo DL, Editors. Philadelphia: Lippincot-Raven; 1966. p. 485-492.
26. Swain AL, Jaskólski M, Housset D, et al. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc Natl Acad Sci U S A. 1993;90(4):1474-1478.
27. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev. 2002;28 Suppl A:13-16.
28. Abuchowski A, Kazo GM, Verhoest CR Jr, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys. 1984;7(2):175-186.
29. Kamisaki Y, Wada H, Yagura T, et al. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther. 1981;216(2):410-414.
30. Wada H, Imamura I, Sako M, et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann N Y Acad Sci. 1990;613:95-108.
31. Keating MJ, Holmes R, Lerner S, et al. L-asparaginase and PEG asparaginase-past, present, and future. Leuk Lymphoma. 1993;10 Suppl:153-157.
32. Fu CH, Sakamoto KM. PEG-ASNase araginase. Expert Opin Pharmacother. 2007;8(12):1977-1984.
33. Ettinger LJ, Kurtzberg J, Voûte PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995;75(5):1176-1181.
34. Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer. 2006;46(1):18-25.
35. Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2004;18(6):1072-1077.
36. Müller HJ, Beier R, da Palma JC, et al. PEG-ASNase araginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol. 2002;49(2):149-154.
37. Kiriyama Y, Kubota M, Takimoto T, et al. Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia. 1989;3(4):294-297.
38. Prager MD, Bachynsky N. Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas. Arch Biochem Biophys. 1968;127(1):645-654.
39. Haskell CM, Canellos GP, Cooney DA, et al. Biocmical and pharmacologic effects of L-asparaginase in man. J Lab Clin Med. 1970;75(5):763-770.
40. Cooney DA, Handschumacher RE. L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol. 1970;10:421-440.
41. Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med. 1971;74(6):893-901.
42. Asselin BL, Ryan D, Frantz CN, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989;49(15):4363-4368.
43. Ueno T, Ohtawa K, Mitsui K, et al. Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia. 1997;11(11):1858-18561.
44. Shimizu T, Kubota M, Adachi S, et al. Pre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity. Int J Cancer. 1992;50(4):644-648.
45. Capizzi RL, Aggarwal K. Asparaginase. In Biochemical Pharmacology of Blood and Blood Forming Agents. Fisher JW, editor. Heidelberg: Springer; 1992. p. 548-565.
46. Park YK, Abuchowski A, Davis S, et al. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct. Anticancer Res. 1981;1(6):373-376.
47. Berg SL, Balis FM, McCully CL, et al. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. Cancer Chemother Pharmacol. 1993;32(4):310-314.
48. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standardrisk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99(6):1986-94. Erratum in Blood. 2002;100(5):1531.
49. Ho DH, Brown NS, Yen A, et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos. 1986;14(3):349-352.
50. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. Clin Oncol. 1993;11(9):1780-1786.
51. Holle LM. Pegaspargase: an alternative? Ann Pharmacother. 1997;31(5): 616-624.
52. Albertsen BK, Jakobsen P, Schrøder H, et al. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemother Pharmacol. 2001;48(1):77-82.
53. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744-2750.
54. 2 PEG-ASNase araginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005;217(6):321-326.
55. Capizzi RL. Asparaginase revisited. Leuk Lymphoma. 1993; 10 Suppl:147-150.
56. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217-226.
57. Ohnuma T, Holland JF, Freeman A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res. 1970;30(9):2297-2305.
58. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol. 1986;8(2):99-104.
59. Appel IM, Pinheiro JP, den Boer ML, et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-ASNase araginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003;17(11):2254-2256.
60. Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991-998.
61. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367-393.
62. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007;109(10):4164-4167.
63. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-ASNase araginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103-111.
64. Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2004;18(6):1072-1077.
65. Haskell CM, Canellos GP. l-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol. 1969;18(10):2578-2580.
66. Broome JD, Schwartz JH. Differences in the production of L-asparagine in asparaginase-sensitive and resistant lymphoma cells. Biochim Biophys Acta. 1967;138(3):637-639.
67. Prager MD, Bachynsky N. Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas. Biochem Biophys Res Commun. 1968;31(1):43-47.
68. Kiriyama Y, Kubota M, Takimoto T, et al. Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia. 1989;3(4):294-297.
69. Hutson RG, Kitoh T, Moraga Amador DA, et al. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol. 1997;272(5 Pt 1):C1691-C1699.
70. Gallagher MP, Marshall RD, Wilson R. Asparaginase as a drug for treatment of acute lymphoblastic leukaemia. Essays Biochem. 1989;24:1-40.
71. Holleman A, den Boer ML, Kazemier KM, et al. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood. 2003;102(13):4541-4546.
72. Faderl S, Thall PF, Kantarjian HM, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999;5(12):4041-4047.
73. Gallagher MP, Marshall RD, Wilson R. l-Asparaginase a drug for treatment of acute lymphoblastic leukemia. Essays Biochem. 1989; 24:1-40.
74. Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969;281(19):1028-1034.
75. Package Insert. Oncaspar (pegaspargase), Rhone-Pooulenc Rorer, Collegeville, PA; 1994.
76. Oettgen HF, Tallal L, Tan CC, et al. Experimental and clinical effects of l-asparaginase. In: Grundman E, Oettegen HF, editors. Clinical Experience with L-asparaginase. New York: Springer; 1970. p. 219-43.
77. Anderson N, Lokich JJ, Tullis JL. L-asparaginase effect on antithrombin-III levels. Med Pediatr Oncol. 1979;7(4):335-340.
78. Priest JR, Ramsay NKC, Bennet AJ, et al. The effect of l-asparaginase on antithrombin, plasminogen and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 1982;100(6): 990-995.
79. Homans AC, Rybak ME, Baglini RL, et al. Effect of l-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol. 1987;5(5):811-817.
80. Gugliotta L, D'Angelo A, Mattioli-Belmonte M, et al. Hypercoagulability during l-asparaginase treatment: the effect of antithrombin III supplementation in vivio. Br J Hematol. 1990;74(4):465-470.
81. Wermes C, von Depka Prondzinski M, Lichtinghagen R, et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr. 1999;158 Suppl 3: S143-S146.
82. Knofler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy-impact of central venous lines. Eur J Pediatr. 1999;158 Suppl 3:S147-S150.
83. Mauz-Körholz C, Junker R, Göbel U, et al. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83(6):840-843.
84. Nguyen DL, Wilson DA, Engleman ED, et al. Serial sonogram to detect pancreatitis in children receiving l-asparaginase. South Med J. 1987;80(9):1133-1136.
85. Samuels BI, Culbert SJ, Okamura J, et al. Early detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography: a preliminary report. Cancer. 1976;38(4):1515-1523.
86. Pochedly C. Neurotoxicity due to CNS therapy for leukemia. Med Pediatr Oncol. 1977;3(1):101-115.
87. Vieira Pinheiro JP, Müller HJ, Schwabe D, et al. Drug monitoring of low-dose PEG-ASNase araginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol. 2001;113(1): 115-119.
88. Taylor CW, Dorr RT, Fanta P, et al. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2001;47(1):83-88.
89. Aguayo A, Cortes J, Thomas D, et al. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1999;86(7):1203-1209.
90. Douer D, Cohen LJ, Peridou LA, et al. Peg-L-asparaginase (PEGASNASE): Pharmacokinetics (PK) and clinical response in newly diagnosed adults with acute lymphoblastic leukemia (ALL) treated with multiagent chemotherapy Blood. 1997;90(Suppl 1):334a.
91. Muss HB, Spell N, Scudiery D, et al. A phase II trial of PEG-Lasparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs. 1990;8(1):125-130.
92. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-1218.
93. Rosen O, Müller HJ, Gökbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol. 2003;123(5):836-841.
94. Holcenberg J, Sencer S, Cohen LJ, et al. Randomised trial of PEG vs native l-asparaginase in children with newly diagnosed acute lymphoblastic leukemia (ALL): CCG study 1962. Blood. 1999;94:628a.
95. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000;96(5):1709-1715.
96. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-ASNase araginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22(9):1665-1679.
97. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther. 2009;9(1):111-119.
98. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(7):1525-1532.
99. van der Eijk AA, Vrolijk JM, Haagmans BL. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med. 2006;354(12):1323-1324.
100. Peters BG, Goeckner BJ, Ponzillo JJ, et al. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary. 1995;30(7):388-393.
101. Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002;24(3):175-181.